Osteoporosis International

, Volume 5, Issue 1, pp 39–46

Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis

  • R. Rizzoli
  • T. Chevalley
  • D. O. Slosman
  • J. -P. Bonjour
Original Article


Corticosteroid-induced osteoporosis, which particularly affects the axial skeleton and the proximal femur, is characterized by a state of low bone remodelling. Fluoride is a potent stimulator of trabecular bone formation which could potentially be useful in the treatment of corticosteroid-induced osteoporosis. We investigated the effects of sodium monofluorophosphate (26 mg/day of fluoride) combined with 1000 mg of calcium (MFP-calcium-treated group), or of calcium alone (control), given for 18 months, on bone mineral density (BMD) of lumbar spine (LS), femoral neck (FN) and midfemoral shaft (FS) in 48 patients with corticosteroid-induced osteoporosis. Mean ages were 49.4±3.1 and 51.6±3.0 years (mean± SEM), duration of corticosteroid therapy 7.5±1.8 and 9.3±1.7 years, and mean daily dose of prednisone 18.2±2.3 and 12.1±1.1 mg in the MFP-calcium-treated group and controls, respectively. Initial BMDs (expressed as theZ-score, i.e. the difference in standard deviations from age- and sex-matched normal subjects) were −1.5±0.2 and −1.2±0.2 for LS, −1.4± 0.2 and −1.3±0.2 for FN, and −0.8±0.3 and −0.6±0.3 for FS, in the MFP-calcium-treated group and controls, respectively. Analysis by linear regression of 6-monthly measurement values revealed BMD changes of +7.8 ±2.2 versus + 3.6±1.3% (p<0.02) for LS, −1.5±1.8 versus +0.9 ±1.8% for FN, and −1.1±1.1 versus −0.5±1.4% for FS after 18 months of follow-up in the MFP-calcium-treated group and controls, respectively. For comparison, 17 patients with idiopathic osteoporosis (mean age 63.9±2.0 years), with initial BMDs of −1.3±0.4, −1.6±0.3 and −0.8±0.4 (Z-score for LS, FN and FS, respectively), received MFP and calcium for 22.1±1.7 months. BMD changes in idiopathic osteoporosis were +9.3±2.7% (p<0.005), −1.3±2.0% and +0.6± 0.9% for LS, FN and FS, respectively. These results indicate that the combination sodium monofluorophosphate and calcium was more efficient than calcium alone in increasing lumbar spine BMD in patients with corticosteroid-induced osteoporosis; neither femoral neck nor femoral shaft BMD was affected. Moreover, these effects were similar in patients with corticosteroid-induced and idiopathic osteoporosis.


Bone mineral density Calcium Corticosteroid Fluoride Osteoporosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989;30:83–103.Google Scholar
  2. 2.
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352–64.Google Scholar
  3. 3.
    Rizzoli R, Slosman DO, Bonjour JP. Unpredictable deleterious effects of long term glucocorticoid therapy on lumbar spine and femoral neck bone mineral density. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress: 1743–4.Google Scholar
  4. 4.
    Sambrook P, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990;5:1211–6.Google Scholar
  5. 5.
    Meunier PJ, Dempster DW, Edouard C, et al. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1984;171:191–200.Google Scholar
  6. 6.
    Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137–41.Google Scholar
  7. 7.
    Reid I, Chapman G, Fraser I, et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 1986;62:379–83.Google Scholar
  8. 8.
    Prummel MF, Wiesinga WM, Lips P, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382–6.Google Scholar
  9. 9.
    Kotowicz MA, Hall S, Hunder GG, et al. Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 1990;33:1487–92.Google Scholar
  10. 10.
    Morris HA, Need AG, O'Loughlin PD, et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990;46:305–8.Google Scholar
  11. 11.
    Heaney RP, Baylink DJ, Johnston CC Jr, et al. Fluoride therapy for the vertebral crush fracture syndrome: a status report. Ann Intern Med 1989;111:678–80.Google Scholar
  12. 12.
    Dure-Smith BA, Kraenzlin ME, Farley SM, et al. Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action. Calcif Tissue Int 1991; (suppl.)49:S64–7.Google Scholar
  13. 13.
    Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl J Med 1990;322:802–9.Google Scholar
  14. 14.
    Meunier PJ. Fluoride therapy for vertebral osteoporosis. In: Munro H, Schlierf G, editors. Nutrition of the elderly. New York: Raven Press, 1992;29:177–85.Google Scholar
  15. 15.
    Bayley TA, Harrison J, Basualdo J, et al. The long term treatment of steroid osteoporosis with fluoride. J Bone Miner Res 1990;5 (Suppl 1):S157–61.Google Scholar
  16. 16.
    Meunier PJ, Briancon D, Chavassieux P, et al. Treatment with fluoride: bone histomorphometric findings. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1989, vol 2. Copenhagen: Osteopress, 1989:824–8.Google Scholar
  17. 17.
    Meys E, Terreaux-Duvert F, Beaume-Six T, et al. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporosis Int 1993;3:322–9.Google Scholar
  18. 18.
    Greenwald M, Brandli D, Spector S, et al. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporosis Int 1992;2:303–4.Google Scholar
  19. 19.
    Slosman DO, Rizzoli R, Buchs B, et al. Comparative study of the performance of X-ray and gadolinium-153 bone densitometers at the level of spine, femoral neck and femoral shaft. Eur J Nucl Med 1990;17:3–9.Google Scholar
  20. 20.
    Uebelhart D, Gineyts E, Chapuy MC, et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87–96.Google Scholar
  21. 21.
    Bonjour JP, Philippe J, Guelpa G, et al. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 1988;9:123–30.Google Scholar
  22. 22.
    Bijvoet OLM, Morgan DB, Fourman P. The assessment of phosphate reabsorption. Clin Chim Acta 1969;26:15–24.Google Scholar
  23. 23.
    Buchs B, Rizzoli R, Slosman D, et al. Densité minérale osseuse de la colonne lombaire, du col et de la diaphyse f émoraux d'un ećhantillon de la population genevoise. Schweiz Med. Wochenschr 1992;122:1129–36.Google Scholar
  24. 24.
    Lo Cascio V, Bonucci E, Imbibo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39–51.Google Scholar
  25. 25.
    Delmas PD, Dupuis J, Duboeuf F, et al. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res 1990;5 (Suppl 1):S143–7.Google Scholar
  26. 26.
    Pouilles JM, Tremollieres F, Causse E, et al. Fluoride therapy in postmenopausal osteopenic women: effect on vertebral and femoral bone density and prediction of bone response. Osteoporosis Int 1991;1:103–9.Google Scholar
  27. 27.
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.Google Scholar
  28. 28.
    Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D-replete elderly patients. Osteoporosis Int 1994 (in press).Google Scholar
  29. 29.
    Reid IR, Ibbertson HK, Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986;44:287–90.Google Scholar

Copyright information

© European Foundation for Osteoporosis 1995

Authors and Affiliations

  • R. Rizzoli
    • 1
  • T. Chevalley
    • 1
  • D. O. Slosman
    • 2
  • J. -P. Bonjour
    • 1
  1. 1.Division of Clinical Pathophysiology (World Health Organization Collaborating Center for Osteoporosis and Bone Disease), Department of MedicineUniversity Hospital of GenevaGenevaSwitzerland
  2. 2.Division of Nuclear Medicine, Department of RadiologyUniversity Hospital of GenevaGenevaSwitzerland

Personalised recommendations